Find a Provider

Peter J. O'Dwyer, MD

Peter J. O'Dwyer, MD Physician

Director, Developmental Therapeutics Program, Abramson Cancer Center
Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Dr. O'Dwyer is a Penn Medicine employed physician.

About Dr. Peter J. O'Dwyer

Recognized by Best Doctors in America 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Anal Cancer
    • Colon Cancer
    • Early Phase Clinical Trials - Developmental Therapeutics
    • Esophageal Cancer
    • Gastrointestinal Carcinoid Tumor
    • Liver Cancer
    • Pancreatic Cancer
    • Rectal Cancer
    • Small Intestine Cancer
    • Stomach (Gastric) Cancer

Board Certification:

  • Internal Medicine, 1981
  • Medical Oncology, 1987
  • Pediatrics, 1983

Conditions & Treatments:

  • Anal Cancer
  • Bile Duct Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gastrointestinal Carcinoid Tumor
  • Gastrointestinal Stromal Tumors (GIST)
  • Liver Cancer
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • parathyroid tumor
  • Rectal Cancer
  • Sinus Cancer
  • Small Intestine Cancer
  • Stomach (Gastric) Cancer
  • Throat Cancer
  • Thyroid Cancer

Practice Locations and Appointments

  • Gastrointestinal Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Dublin Trinity College
Residency: Saint Patrick's Hospital and Health Sciences Center
Residency: Hammersmith Hospital
Residency: The Waterbury Hospital Health Center
Residency: Greater Baltimore Medical Center
Fellowship: University of Maryland Hospital
Fellowship: National Cancer Institute


11th NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy, 2nd International Workshop on Targeted Therapy in Colorectal Cancer, 3rd International Pharmacodynamics Workshop, Tidewater, Virginia, 7th International Meeting on Chemical Modifiers of Cancer Treatment, Adjuvant Colon Studies, NSABP, American Association for Cancer Research, American Association for the Advancement of Science, American Cancer Society, American College of Physicians, American Federation Clinical Research, American Society of Clinical Oncology, American Society of Clinical Pharmacology and Therapeutics, American Society of Hematology, American Society of Preventive Oncology, Center for Biomedical Continuing Education, Center for Biomedical Continuing Education, College of Physicians Philadelphia, Colon Cancer Alliance, Eastern Cooperative Oncology Group, EORTC 1st Translational Research Symposium, Brussels, EORTC Protocol Review Committee, Festschrift for Dr. Patrick Creaven, Buffalo, Gastrointestinal Cancer, International Congress of Chemotherapy, International Meta-Analysis Group in Cancer, International Workshop on Targeted Therapy in Colorectal Cancer, National Cancer Institute, New Agents/Pharmacology, CALGB, Pennsylvania Oncology Society, Pharmacokinetics and Metabolism Group, EORTC, SPORE in pancreatic cancer, NYU, Summit on Clinical Trials, Washington, DC, Summit V, Workgroup on Trial Design, U.S.-Japan Cancer Research Symposium, Tokyo, Working Group on ECOG/EORTC Coordination,


Dr. O'Dwyer is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Selected Publications:

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL: Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV : 2003.

Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy Cancer Chemother Pharmacol : 2003.

Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors : 2003.

Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention Biochem Pharmacol : 2003.

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas : 2003.

Flaherty KT, O'Dwyer PJ: Phase II trials in oncology Anticancer Drug Development Guide : 2003.

Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy Drug Resistance Updates : 2003.

O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer Semin Oncol 30 (3 Supp 6): 78-87,2003.

Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies : 2003.

Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer : 2003.

Academic Contact Info

16 Penn Tower
3400 Spruce Street

Philadelphia, PA 19104
Phone: (215) 662-7606
Fax: (215) 349-8551
Patient appointments: 800-789-PENN (7366)

Related Links